ECOR

144 - electroCore, Inc. (0001560258) (Subject)

D - electroCore, Inc. (0001560258) (Filer)

4 - electroCore, Inc. (0001560258) (Issuer)

4 - electroCore, Inc. (0001560258) (Issuer)

3 - electroCore, Inc. (0001560258) (Issuer)

ROCKAWAY, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Needham Virtual Healthcare Conference taking place virtually on April 15, 2026. Joshua Lev, Interim President and Chief Financial Officer, will host a company presentation at 2:15 pm ET and participate in one-on-one meetings throughout the day. DATE: April 15, 2026TIME: 2:15 pm ET Investors attending the conference who are interested in scheduling a meeting with management can do so by contacting their Needham representative, or by emailing ECOR Investor Relations at investors@electroco

ROCKAWAY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the enrollment of the first eight patients in a clinical study being conducted by Acacia Clinics in collaboration with the Vagus Nerve Society. As previously announced, the study is designed to evaluate the safety and effectiveness of electroCore's gammaCore™ non-invasive vagus nerve stimulation (nVNS) device as an adjunctive treatment for symptoms associated with PTSD. The study is expected to enroll up to 40 adult participants and will assess outcomes over a 12-week treatment period. The primary safety endpoint is the incide

4 - electroCore, Inc. (0001560258) (Issuer)

ROCKAWAY, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the publication of new clinical findings in Frontiers in Neuroscience titled "Adjunctive non-invasive vagus nerve stimulation for chronic mild traumatic brain injury with comorbid post-traumatic stress disorder: a post-hoc analysis" by Drs. Michael Ament, Peter Staats, Norianne Theresa Ingram, and Emily Leonard, demonstrating the potential benefits of adjunctive non-invasive vagus nerve stimulation (nVNS) in patients with chronic mild traumatic brain injury (mTBI) and comorbid post-traumatic stress disorder (PTSD). The publicat

ROCKAWAY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (the "Company"), (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Seth Abrams will join electroCore, effective April 1, 2026, as the Company's VP, Sales, and Michael Fox will join electroCore, effective April 13, 2026, as the Company's Chief Operating Officer. The Compensation Committee of electroCore's Board of Directors granted 30,000 restricted stock units ("RSUs") to Mr. Abrams and 70,000 RSUs to Mr. Fox in connection with the commencement of their employment. The RSUs were granted as an inducement material to their commencement of employment pursuant to NASDAQ Listin

ROCKAWAY, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the issuance of two new U.S. patents that further bolster the Company's already extensive intellectual property portfolio. These additions underscore electroCore's position as a leader in non-invasive vagus nerve stimulation (nVNS) technology and demonstrate how a nimble small-cap innovator can build one of the most robust patent portfolios in the field. The newly issued patents are: • U.S. Patent No. 12,208,263, entitled "Devices and Methods for Vagal Nerve Stimulation" was issued on January 28, 2026 and covers innovative meth

4 - electroCore, Inc. (0001560258) (Issuer)

S-8 - electroCore, Inc. (0001560258) (Filer)

10-K - electroCore, Inc. (0001560258) (Filer)

8-K - electroCore, Inc. (0001560258) (Filer)

Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness sales Announces the retirement of Dan Goldberger as Chief Executive Officer in addition to other key executive management changes Company to host a conference call and webcast today, March 19, 2026, at 4:30pm EDT ROCKAWAY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced full year 2025 financial results. Reported record full year of 2025 revenue of $32.0 million, an increase of a

ROCKAWAY, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a bioelectronic medicine and wellness company, announced today that management will participate in the 38th Annual Roth Conference March 22-24 at the Ritz-Carlton in Laguna Niguel, California. Joshua Lev, Chief Financial Officer, will host one-on-one meetings at the conference. Investors attending this event who are interested in scheduling a meeting with management can do so by contacting their respective Roth representative, or by emailing investors@electrocore.com for more information. About the Roth Capital Partners ConferenceThe Annual ROTH Conference is one of the largest in the nation for small-cap

ROCKAWAY, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the fourth quarter and full year ended December 31, 2025, after the close of the market on Thursday, March 19, 2026. Management will host a webinar at 4:30 PM EDT to review the financial results and answer questions. Investors can access the webinar using the details below: Thursday, March 19, 4:30 PM EDTDial-In: (646) 931-3860Webinar ID: 886 9421 4883Passcode: 014212Registration Link: Click here to participate and ask questions on the call. About electroCore, Inc.electroCore, I

4 - electroCore, Inc. (0001560258) (Issuer)

4 - electroCore, Inc. (0001560258) (Issuer)

ROCKAWAY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced that Acacia Clinics and the Vagus Nerve Society have launched a new research initiative to explore the extent to which gammaCore™ Sapphire, electroCore's non-invasive vagus nerve stimulator (nVNS), can be used as an adjunctive treatment of symptoms associated with PTSD. The study entitled "Non-Invasive Vagus Nerve Stimulation (nVNS) for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder," will be led by Danielle DeSouza MSc, PhD, VP of Research at Acacia Clinics ("the Investigator"). The study w

8-K - electroCore, Inc. (0001560258) (Filer)

Record revenue of approximately $31.8 - $32.0 million for full-year 2025 and approximately $9.0 - $9.2 million for the three months ended December 31, 2025 Revenue growth of approximately 26% over full-year 2024Cash, cash equivalents, and marketable securities ("Total Cash") balance of approximately $11.6 million as of December 31, 2025 ROCKAWAY, N.J., Jan. 20, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today provided select unaudited preliminary financial guidance for the full year and fourth quarter of 2025. Financial GuidancePreliminary unaudited financial guidance for the full year and fourth quarter

4 - electroCore, Inc. (0001560258) (Issuer)

4 - electroCore, Inc. (0001560258) (Issuer)